免费看裸体 视频阳春-免费看裸体 网水视频-免费看裸体 网站-免费看裸体 网站视频-免费看裸体 网站涂抹-免费看裸体 阳春

Cell Therapy
Universal Cell Platform
Quikin CAR-T Platform
Enhanced T Cell Platforms

Quikin CAR-T Platform


The Quikin CAR-T Platform (Quikin CART) generates T cell products with gene knockout and stable integration of CAR cassette in one step through CRISPR gene editing technology. As a new generation of CAR-T platform, it has several advantages, including simplified manufacturing process, shortened preparation time, higher product uniformity and avoiding the risk of tumorigenesis caused by random integration. The product with integration of anti-CD19 CAR cassette into PD1?locus combines PD1 immune checkpoint inhibition with CART anti-tumor activity. This platform has the potential to prepare enhanced CAR-T cells with gene knockout of multiple immune checkpoints, rapidly produce universal CAR-T cells and prepare dynamically regulated CAR-T cells with high safety, thus providing strong technical support for future improvement of CAR-T cells.


The development of the era of gene therapy

In 2023, the world's first all human targeted BCMA CAR-T therapy "FUCASO" (Equecabtagene Autoleucel) was approved for sale in China for the treatment of recurrent or refractory multiple myeloma (R/R MM)
In 2022, Cilta cel, the first CAR-T cell therapy for the treatment of r/r MM in China, was approved by the FDA for marketing
In 2021, China's first CAR-T product, Aquilensai injection, was approved for marketing by the Chinese NMPA for post-treatment relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
In 2020，CRISPR/Cas9 gene editing technology wins Nobel Prize in Chemistry
In June 2019, zynteglo, the world's first gene therapy drug ,was approved for marketing by the EU EMA for the treatment of thalassemia
In May 2019, Zolgensma, the world's first gene therapy drug,was approved for marketing by the FDA for the treatment of SMA
In 2018, the first CRISPR/Cas9-based in vivo gene therapy clinical trial (EDIT-101) was approved by the FDA for the treatment of Leber Congenital Amaurosis Type 10 (LCA)
In 2017, Kymriah, the world's first CAR-T product, received FDA approval to market for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL)
In 2016, the first generation of single-base editors were developed
In November 2013, the third generation gene editing technology CRISPR/Cas9 (clustered regularly spaced short palindromic repeats) was introduced
In 2012, Glybera, the world's first AAV gene therapy drug, was approved for marketing by the EU EMA for the treatment of lipoprotein lipase deficiency (LPLD)
In 2010, TALENs (transcription activation-like effector nucleases), a second-generation gene editing technology, was introduced
In 2003, Gendicine, the world's first gene therapy drug, was approved for marketing by the NMPA in China for the treatment of head and neck squamous cell carcinoma (HNSCC)
In 2001, the first generation of gene editing technology ZFNs (zinc finger nucleases) was introduced
In 1990, the world's first clinical trial of gene therapy was approved by the FDA for the treatment of adenosine deaminase deficiency (ADA-SCID)
Back to top
主站蜘蛛池模板： 69仙踪林精品视频一区二区 | 亚洲精品无码一区二区牛牛 | 91干逼网| 亚洲AV秘 无码一区二区三区 | 国产精品三级久久久久久电影 | 熟女 人妻 人妻の视频 | 黄色网址在线播放 | 在线视频一区二区 | 日韩XXXXⅩ | 69精品一区二区三区无码吞精 | 免费看无码一级A片放24小时 | AV高清无码在线观看 | 国产裸体美女无遮挡 | 亚洲AV无码乱码精品护士岛国 | 免费播放婬乱男女婬视频国产 | .精品人妻一区二区 | 黄色无码网站 | 69精品人人槡人妻人人玩简单 | 久久福利导航 | 国产乱人乱偷精品视频 | 国产麻豆剧传媒精品国产AV杜鹃 | 少妇AV无码 | 天天干天天爽 | 隔着内裤和伴郎做了h | 无码精品A∨在线观看中文偷拍 | 69成人电影 | 波多野结衣av作品一区二区三区 | 国产精品人妻人伦a 6 2v久久69 | 无码在线二区 | 日本一本二本三区免费 | 韩国三级无码一区 | 国产无遮挡A片又黄又爽小直播 | 国产成人片在线观看 | 午夜精品久久久久久久无码软件 | 无码AV免费在线 | 91麻豆影院 | 国产A级成人婬片1976 | 无码在线免费 | 无码人妻丰满熟妇**网站牛牛 | A片无码网址 | www日本高清 |